Oxycyte

From Wikipedia, the free encyclopedia

Oxycyte is a perfluorocarbon based oxygen therapeutic currently under development by Synthetic Blood International. Phase II-b clinical trials are scheduled to begin in Q2 2008 to determine the safety and efficacy of the substance.

[edit] Treatment of Traumatic Brain Injury

Initial trials of Oxycyte have focused on the application of treatment for Traumatic Brain Injury due to Oxycyte's ability to transfer oxygen through the blood 50 times more effectively than actual blood.

The substance is able to carry approximately four times more oxygen than red blood cells and is able to reach damaged and blocked blood vessels even when red blood cells cannot.

[edit] Phase II-b Clinical Trials

Synthetic Blood International has submitted a clinical protocol with the U.S. Food and Drug Administration to proceed with a multi-center, double-blind, palacebo-controlled study of Oxycyte. The trials would enroll up to 300 patients to determine the safety and efficacy of the substance.

[edit] References

Official Website: Synthetic Blood International, Inc.
PBS Wired Science: "Blood Simple"
Miami Herald: "Artificial blood goes from science fiction to science fact"
Popular Science: "Better than Blood"
Synthetic Blood International, Inc. Announces Filing of Protocol for Phase II-b Oxycyte Clinical Trial